Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial.
about
Topical treatments for chronic plaque psoriasisTopical treatments for chronic plaque psoriasisSite-specific immunosuppression in vascularized composite allotransplantation: prospects and potentialOutcomes in randomized controlled trials in psoriasis: what has changed over the last 20 years?Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Long-term blood vessel removal with combined laser and topical rapamycin antiangiogenic therapy: implications for effective port wine stain treatment.Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation.Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration.Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.Calcineurin inhibitors and rapamycin: cancer protection or promotion?Proteogenomic analysis of psoriasis reveals discordant and concordant changes in mRNA and protein abundance.Allergic contact dermatitis caused by topical sirolimus used as an adjuvant for laser treatment of port wine stains.Basic immunosuppressive drugs outside solid organ transplantation.Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseasesInhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.Severe psoriasis treated with a new macrolide: everolimus.Non-invasive imaging techniques in the diagnosis of skin diseases.Phytochemical modulation of the Akt/mTOR pathway and its potential use in cutaneous disease.Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway.Ribosomal protein S6 is hyperactivated and differentially phosphorylated in epidermal lesions of patients with psoriasis and atopic dermatitis.Topical Therapies in Psoriasis.Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis.Classic Kaposi's sarcoma treated with topical rapamycin.Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin.Topical rapamycin (sirolimus) for facial angiofibromas.Visible effects of rapamycin (sirolimus) on human skin explants in vitro.Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies.TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin.Topical application of rapamycin ointment ameliorates Dermatophagoides farina body extract-induced atopic dermatitis in NC/Nga mice.
P2860
Q24198258-4942C43B-6DA9-4741-AB5A-85932CC317EDQ24241239-5D5F4FF2-5432-46BD-98CB-400AFF2A56DFQ27027795-A303067F-C23F-425B-A4EC-0AAC94006723Q33301650-31B45F6B-09C0-4C7B-A13B-9BA1C0D0DF1BQ33316872-11379FBE-DEE9-46D3-8B62-1E4257E592F0Q33532221-B5B372E7-90F9-4B1A-BA0D-A979F8F5121AQ33897776-15A9B151-A607-4540-AFD3-7A2553E1C7D9Q33990813-3B419CBF-9646-489C-8527-4747CA9AA037Q34086311-F1A5E2B7-1A6A-4363-89DB-73BE0E498CC8Q34436120-4E11219E-7797-4A92-A7B8-33B0534F9083Q34501488-CC251A34-FC0B-48FB-BB11-48239078D1E6Q34578721-999DFA3B-8D6A-4019-8343-03DED53AB4C9Q35922976-690D78CE-F2F0-4495-B844-AADD335F3E54Q36091983-457C8F23-52EC-4EDC-AB68-0F875BADEDA3Q36407314-8C3DDB38-BDD1-45C6-9262-586E19894B6BQ36425959-FD820532-BEAF-4B9A-B266-D01C48051ECCQ36649878-E434DC94-A25F-4633-B5A5-ECA9CCC26D79Q36708370-9C968DE4-79A3-4A71-91AA-D4D5C930DAFDQ38088750-67FACBDE-B7E6-4C6D-B2F9-1812C7E9B4C3Q38223953-23220970-3543-466A-997C-C1358E3302F7Q38841006-D7068713-2CB8-4A49-8A9A-EE896BE37E31Q39413456-C93E3126-F80A-4D20-8FFA-0BEFEE55D4D3Q41068232-10B123A7-980E-45CC-A4C8-7243BC8DE991Q41884115-166BBE1B-CAA8-4075-8ADA-353580D2DE92Q42183676-62055B57-CA4A-4ECC-8E33-7211DEE0EF62Q42520536-B746394F-C099-4C4D-9374-E03910CF6C92Q43246829-56D2F65C-6F43-4581-85BB-25E94A518DFCQ45849022-66D611F6-CD5B-4342-B693-0740820C48B1Q47351188-2A9DB5F0-7CA9-47CB-8D9E-64280B214E74Q48362769-4A336545-1C84-43A6-932E-F08EC1BF545FQ54346708-A012DC2A-BFCE-4C7C-8496-BBC65ACC23BC
P2860
Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Treatment of psoriasis with to ...... andomized, double-blind trial.
@en
Treatment of psoriasis with to ...... andomized, double-blind trial.
@nl
type
label
Treatment of psoriasis with to ...... andomized, double-blind trial.
@en
Treatment of psoriasis with to ...... andomized, double-blind trial.
@nl
prefLabel
Treatment of psoriasis with to ...... andomized, double-blind trial.
@en
Treatment of psoriasis with to ...... andomized, double-blind trial.
@nl
P2093
P2860
P1476
Treatment of psoriasis with to ...... andomized, double-blind trial.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2133.2005.06438.X
P407
P577
2005-04-01T00:00:00Z